Carson City, NV, United States of America

Scott B Meikrantz



Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Scott B. Meikrantz

Introduction

Scott B. Meikrantz, based in Carson City, NV, stands as a distinguished inventor in the field of pharmaceuticals. With a focus on developing therapeutic innovations, he has made significant strides in enhancing medical treatments. His pioneering work has led to the filing of a notable patent that addresses critical healthcare challenges.

Latest Patents

One of Scott B. Meikrantz's significant achievements is his patent titled "Benzenesulfonylimine derivatives as inhibitors of IL-1 action." This invention plays a crucial role in the inhibition of interleukin-1 (IL-1) action, representing a promising development in therapeutic interventions for inflammatory diseases.

Career Highlights

Currently, Scott is employed at Merrell Pharmaceuticals, Inc., where he actively contributes to the advancement of medical research and innovation. His journey as an inventor is marked by a commitment to improving the efficacy of pharmaceutical products and their impact on patient care.

Collaborations

Throughout his career, Scott has collaborated with several esteemed colleagues, including Boyd L. Harrison and George Ku. These partnerships highlight the collaborative nature of research and innovation within the pharmaceutical industry, fostering an environment where new ideas can flourish.

Conclusion

Scott B. Meikrantz's contributions to the field of pharmaceuticals, illustrated by his patent and collaborations, underscore the vital role of inventors in advancing medical science. His innovative spirit continues to inspire ongoing research and development within the industry, paving the way for future breakthroughs in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…